Fistula - Pipeline Review, H1 2012

Global Markets Direct, May 2012, Pages: 25

Fistula – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Fistula - Pipeline Review, H1 2012', provides an overview of the Fistula therapeutic pipeline. This report provides information on the therapeutic development for Fistula, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fistula. 'Fistula - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Fistula.
- A review of the Fistula products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fistula pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Fistula.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fistula pipeline depth and focus of Fistula therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Fistula Therapeutic Products under Development, Key Players in Fistula Therapeutics, Fistula Pipeline Overview, Fistula Pipeline, Fistula Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fistula Overview
Therapeutics Development
An Overview of Pipeline Products for Fistula
Fistula Therapeutics under Development by Companies
Fistula Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Fistula Therapeutics – Products under Development by Companies
Fistula Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Fistula Therapeutics Development
Fistula – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Pasireotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adipoplus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adipose-Derived Stem Cells Without Expansion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fistula Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Fistula, H1 2012
Products under Development for Fistula – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Fistula Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Fistula, H1 2012
Products under Development for Fistula – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Alzheimer's Disease – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Bipolar Disorder (Manic Depression) – Pipeline Review, H1 2013
• Peanut Allergy – Pipeline Review, H1 2013
• Erectile Dysfunction – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013